Evaluation of Antiplatelet Therapy Related to Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) Values in Relation to the Risk of Recurrent Stroke

Stroke is a medical emergency with significant mortality and morbidity, often influenced by platelet aggregation. Antiplatelet agents are crucial in stroke prevention, as they inhibit platelet function and reduce thrombus formation. Despite antiplatelet therapy, some patients experience recurrent strokes, necessitating further investigation into coagulation parameters like Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT). This study aims to explore the relationship between antiplatelet therapy and PT/APTT values in stroke patients to assess the risk of recurrent strokes. A comparative study was conducted on two groups of stroke patients: those using aspirin therapy and those not using it. PT and APTT measurements were taken at the start and end of a three-month observation period. Data were analyzed quantitatively, focusing on PT and APTT changes in each group. Results: PT values increased more significantly in the Non-Aspirin group (16.32%) compared to the Aspirin group (11.98%). APTT values also increased more in the Non-Aspirin group (4.97%) compared to the Aspirin group (4.73%). However, the statistical significance of the differences in PT and APTT between the groups was not observed (p > 0.05). The study concludes that there is no significant difference in PT and APTT values between patients using clopidogrel alone or in combination with aspirin, indicating no enhanced risk of recurrent strokes based on these parameters.